FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
|Articles|November 25, 2021
A Psychiatrist's Reflections for Thanksgiving
Author(s)Frank A. Clark, MD
Being thankful, reflective, and hopeful...
Advertisement
POETRY FOR INCLUSION
Gratitude—the endless
noun that pursues
fractures
hearts seeking
relationship repair
this season
Blessing—the cosmic
noun that searches
feeble knees
seeking durability
for the spiritual
journey
Recognition—the forgotten
noun that bemoans
Indigenous oppression
seeking resurgence
of cultural
identity
Respect—the invisible
noun that desires
stagnant opaque
minds seeking
intellectual
growth
Appreciation—the enduring
noun that replenishes
collapsed lungs
seeking to breath
molecules of integrated
love
Dr Clark is an outpatient psychiatrist at Prisma Health-Upstate and clinical associate professor at the University of South Carolina School of Medicine, Greenville. He served on the American Psychiatric Association’s Task Force to Address Structural Racism Throughout Psychiatry, and he currently serves as the Diversity and Inclusion section editor and advisory board member for Psychiatric TimesTM.
Advertisement
Related to this article
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
5